In patients with myasthenia gravis, the surgical removal of the thymus gland, called thymectomy, added "quality adjusted life ...

The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...

Newer FDA-approved treatments for myasthenia gravis (MG) include FcRn blockers and complement inhibitors, which offer targeted symptom control beyond traditional steroids.

Johnson & Johnson (NYSE:JNJ) has reported new data from its Phase 3 Vivacity-MG3 trial showing that its therapy IMAAVY ...

The FDA granted Priority Review to the supplemental BLA (sBLA) for efgartigimod alfa-fcab for the treatment of adults with acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia ...

Tuan Vu, MD, professor and division director of Neuromuscular Medicine & Electromyography at USF Health, discussed the safety ...

This year’s American Academy of Neurology meeting included a presentation that could one day set a new treatment standard for ...

USA: The investigational siRNA therapy cemdisiran met both its primary and a key secondary endpoint in the phase III NIMBLE ...

Through 120 weeks of follow-up, nipocalimab delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+ ...

Myasthenia gravis is a chronic autoimmune disorder that disrupts nerve-to-muscle signaling, causing weakness. Modern treatments help many people live typical life spans and enter remission.

Approximately 70 to 300 million individuals worldwide are living with myasthenia gravis, an antibody-mediated autoimmune disorder that adversely affects neuromuscular junction function. “Research has ...

The program is specifically designed to remove critical barriers to proper nutrition while helping myasthenia patients improve their daily quality of life, treatment adherence, and overall health.